Human body will pay more for anti-infection

Evidence from the study of a research team led by Tobias Lenz and Shamil Sunyaev conducted researcher using recombinant mouse proteins and found that the variations of deleterious gene may be the cost of our genetic diversity pays in other ways which are advantageous to us. They analyzed a group of immune system proteins to help to detect foreign molecules. These genes of these proteins contain many variation points. This diversity ensures our immune system to recognize a wide range of pathogens.

The selective special form retains this change of immune proteins within a group: scientists describe it as balancing selection. The results it produces is that when a gene of several alternative variants conferred a survival advantage, it will not be selected to eliminate.

Scientists suspect that balancing selection can sometimes lead to protection against harmful gene variants. They used the example of immune system genes to conduct computer simulation of different types of choices. In these tests, they found that balancing selection not only increases the diversity of immune proteins, but also affects the adjacent DNA fragments. At the same time, reducing the total number of variable sites increases the frequency of these variants in the population - even if they are harmful.

They then compared simulation results and the genetic analysis data of 6,500 people. The analysis confirmed their suspicions. Harmful genes can escape natural selection. "I did not expect that higher pathogen resistance may lead to some accumulation of deleterious mutations, but this mutation in the crowd sustained level surprised me. It will be interesting that the number of human genetic diseases can be traced back to the pathogen we are exposed to in the development process, "Tobias said.

Next, the researchers want to check out whether the balancing selection of other sites in the genome is associated with the frequent occurance of harmful genes in the populations. Flarebio offers recombinant proteins of good quality such as recombinant Cdh10 at competitive prices.